Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
2. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008;14:295–314.10.1111/j.1755-5949.2008.00059.xSearch in Google Scholar PubMed PubMed Central
3. Martin R, Schurenkamp J, Gasse A, Pfeiffer H, Kohler H. Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. Int J Legal Med 2013;127:593–601.10.1007/s00414-012-0796-1Search in Google Scholar PubMed
4. Klette KL, Horn CK, Stout PR, Anderson CJ. LC-MS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions. J Anal Toxicol 2002;26:193–200.10.1093/jat/26.4.193Search in Google Scholar PubMed
5. Gagajewski A, Davis GK, Kloss J, Poch GK, Anderson CJ, Apple FS. False-positive lysergic acid diethylamide immunoassay screen associated with fentanyl medication. Clin Chem 2002;48:205–6.10.1093/clinchem/48.1.205Search in Google Scholar
©2017 Walter de Gruyter GmbH, Berlin/Boston